IL2 and rheumatoid arthritis: The symptoms of RA were significantly reduced after the intravenous administration once per week for three weeks, and the expression of TNF-α, IL-1β and MMP-3 was reduced sharply, which confirmed that IL-2/15 receptor β chain could be a potential target for RA treatment (Figure 7) [60].